MX391725B - Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. - Google Patents

Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Info

Publication number
MX391725B
MX391725B MX2018012655A MX2018012655A MX391725B MX 391725 B MX391725 B MX 391725B MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 391725 B MX391725 B MX 391725B
Authority
MX
Mexico
Prior art keywords
compounds
treatment
methods
neurological
cardiovascular conditions
Prior art date
Application number
MX2018012655A
Other languages
English (en)
Spanish (es)
Other versions
MX2018012655A (es
Inventor
James D Lechleiter
Kenneth A Jacobson
Theodore E Liston
William S Korinek
Original Assignee
Astrocyte Pharmaceuticals Inc
Univ Texas
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrocyte Pharmaceuticals Inc, Univ Texas, Us Health filed Critical Astrocyte Pharmaceuticals Inc
Publication of MX2018012655A publication Critical patent/MX2018012655A/es
Publication of MX391725B publication Critical patent/MX391725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018012655A 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. MX391725B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325860P 2016-04-21 2016-04-21
PCT/US2017/028996 WO2017185061A1 (en) 2016-04-21 2017-04-21 Compounds and methods for treating neurological and cardiovascular conditions

Publications (2)

Publication Number Publication Date
MX2018012655A MX2018012655A (es) 2019-09-06
MX391725B true MX391725B (es) 2025-03-21

Family

ID=60022855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012655A MX391725B (es) 2016-04-21 2017-04-21 Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.

Country Status (12)

Country Link
US (7) US9789131B1 (https=)
EP (2) EP4414027A3 (https=)
JP (3) JP7109005B2 (https=)
KR (2) KR102445887B1 (https=)
CN (2) CN109310695B (https=)
AU (2) AU2017254720B2 (https=)
CA (1) CA3020490A1 (https=)
EA (1) EA201892008A1 (https=)
ES (1) ES2989621T3 (https=)
IL (2) IL289423B2 (https=)
MX (1) MX391725B (https=)
WO (1) WO2017185061A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3214937T3 (pl) 2014-11-07 2024-10-14 Basf Se Mieszaniny szkodnikobójcze
RU2754614C2 (ru) 2016-03-16 2021-09-03 Басф Се Применение тетразолинонов для борьбы с устойчивыми фитопатогенными грибами на злаковых культурах
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
WO2017157920A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL276358B2 (en) * 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
CA3115555A1 (en) * 2018-05-26 2019-12-05 Primetime Life Sciences, Llc Compounds and methods for modulation of g-protein-coupled receptors
WO2020061211A1 (en) * 2018-09-18 2020-03-26 Saint Louis University Use of highly-selective adenosine 3a receptor subtype agonists
EA202190576A1 (ru) * 2018-09-26 2021-09-03 Астросайт Фармасьютикалс, Инк. Полиморфные соединения и их применение
JP7282324B2 (ja) * 2018-12-11 2023-05-29 株式会社島津製作所 イオン化装置、質量分析装置および流体試料の分析方法
US20220218712A1 (en) * 2019-02-25 2022-07-14 Saint Louis University Treatment of alzheimer's disease
SG11202111084WA (en) * 2019-05-06 2021-11-29 Ferrer Int Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof
WO2022232810A1 (en) * 2021-04-28 2022-11-03 Astrocyte Pharmaceuticals, Inc. Purine nucleosides, their intermediates, and methods of preparation thereof
WO2023091791A1 (en) * 2021-11-22 2023-05-25 Astrocyte Pharmaceuticals, Inc. Methods of treating neurological and cardiovascular conditions
EP4476235A4 (en) * 2022-02-10 2026-02-18 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration
EP4611765A2 (en) * 2022-11-03 2025-09-10 Astrocyte Pharmaceuticals, Inc. Fast-dissolving dosage forms and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69428536T2 (de) * 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
US7557092B2 (en) 2002-11-21 2009-07-07 University Of Utah Research Foundation Purinergic modulation of smell
DE602004006895T2 (de) * 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007139775A2 (en) 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20100047798A1 (en) 2006-11-08 2010-02-25 Thomas Jefferson University Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
US20090088403A1 (en) 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
DE102007055529A1 (de) 2007-08-06 2009-02-12 Rhode & Schwarz Gmbh & Co. Kg Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
WO2009050199A1 (en) 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
US20100256086A1 (en) 2007-11-23 2010-10-07 Bar-Ilan Univetrsity Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2429565A4 (en) 2009-04-15 2012-11-14 Univ California NEURONIC OR NERVE PEPTIDES AND APTAMERS
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
ES2654363T3 (es) 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
EA034135B9 (ru) 2013-03-13 2020-04-10 Тафтс Юниверсити Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
US20150087613A1 (en) 2013-09-26 2015-03-26 Saint Louis University Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
WO2015080940A1 (en) 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US20160024135A1 (en) 2014-07-27 2016-01-28 Zhejiang Subtropical Crops Research Institute Adenosine receptor activation reagent and the uses of thereof
CN104873531B (zh) * 2015-05-06 2019-04-23 浙江省亚热带作物研究所 一种腺苷受体激动试剂及其用途
EP3253388A4 (en) 2015-02-04 2018-11-21 Baker Heart and Diabetes Institute A method of treatment and compounds for use therein
CN107847740A (zh) 2015-02-24 2018-03-27 加尔瓦尼生物电子有限公司 神经调节设备
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
US10683292B2 (en) 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
IL276358B2 (en) 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
KR102602990B1 (ko) 2018-06-27 2023-11-17 에스케이하이닉스 주식회사 전원 공급 장치 및 이를 포함하는 전자 장치
EA202190576A1 (ru) 2018-09-26 2021-09-03 Астросайт Фармасьютикалс, Инк. Полиморфные соединения и их применение
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2022232810A1 (en) 2021-04-28 2022-11-03 Astrocyte Pharmaceuticals, Inc. Purine nucleosides, their intermediates, and methods of preparation thereof
WO2023091791A1 (en) 2021-11-22 2023-05-25 Astrocyte Pharmaceuticals, Inc. Methods of treating neurological and cardiovascular conditions

Also Published As

Publication number Publication date
US20220305044A1 (en) 2022-09-29
MX2018012655A (es) 2019-09-06
US10265338B2 (en) 2019-04-23
KR20190006501A (ko) 2019-01-18
CN114903903A (zh) 2022-08-16
IL289423A (en) 2022-02-01
NZ747047A (en) 2025-02-28
EP3445368B1 (en) 2024-07-17
CN109310695A (zh) 2019-02-05
US9789131B1 (en) 2017-10-17
EA201892008A1 (ru) 2019-06-28
EP3445368C0 (en) 2024-07-17
AU2017254720A1 (en) 2018-11-01
US20180021363A1 (en) 2018-01-25
EP3445368A1 (en) 2019-02-27
ES2989621T3 (es) 2024-11-27
IL289423B2 (en) 2026-03-01
US12239654B2 (en) 2025-03-04
CA3020490A1 (en) 2017-10-26
WO2017185061A1 (en) 2017-10-26
KR102445887B1 (ko) 2022-09-21
BR112018071560A2 (pt) 2019-02-12
AU2017254720B2 (en) 2023-02-02
US12390483B2 (en) 2025-08-19
US20250345353A1 (en) 2025-11-13
JP2019515920A (ja) 2019-06-13
AU2023202694A1 (en) 2023-05-18
IL262487B (en) 2022-02-01
US11484545B2 (en) 2022-11-01
IL289423B1 (en) 2025-11-01
EP4414027A3 (en) 2024-11-13
EP4414027A2 (en) 2024-08-14
JP7709141B2 (ja) 2025-07-16
US20200046751A1 (en) 2020-02-13
KR20220132042A (ko) 2022-09-29
EP3445368A4 (en) 2019-12-18
US10953031B2 (en) 2021-03-23
AU2023202694B2 (en) 2025-07-10
IL262487A (en) 2018-12-31
JP2025084908A (ja) 2025-06-03
JP7109005B2 (ja) 2022-07-29
JP2022088642A (ja) 2022-06-14
CN109310695B (zh) 2022-04-01
US20230165887A1 (en) 2023-06-01
US20220000899A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
UY37018A (es) Inhibidores bicíclicos de pad4
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX376201B (es) Compuestos inhibidores de metaloenzima.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
EP3630102C0 (en) FORMULATIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
BR112017007472A2 (pt) 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
UA117779C2 (uk) Піразини як модулятори gpr6
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX379776B (es) Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis.
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos